Defence Therapeutics Inc., a leading biotechnology company modernising an exclusive intracellular delivery platform that allows more effective, safe and potent radiotherapeutic and antibody-related treatments, has introduced its new Scientific Advisory Board (SAB), involving leaders such as Danny Chui, Brendan Hussey and Rob Leanna.
The Defence’s Accum®-Antibody drug conjugate (ADC) program has now touched the laboratory validation door, illustrating a noteworthy elevation in intracellular accumulation and an enhanced efficacy level for Accum®-improved ADCs. Defence retaining its consistency in advancing Accum®-allowed ADC programs, the new Scientific Advisory Board will be joining in to deliver technical, strategic and scientific guidance, reframing the program's scientific and direction priorities.
The PhD, MBA, Chief Scientific Officer of Defence Therapeutics, Maxime Parisotto, said, “Our strong Scientific Advisory Board mutually brings intensified expertise throughout the antibody-related therapeutics, translational biology, biotech development, biomanufacturing and intracellular delivery. Brendan, Rob and Danny have equally supported the complementary ideas that will power up our development and scientific smart strategy as we modernise Accum®- sponsored therapeutics.”
The significant experience and background of the Scientific Advisory Board members mirror the scope of the expertise needed to upgrade Accum® from the promising preclinical development for scale and translation. Rob Leanna is an impressive pharmaceutical industry veteran holding an enlarged experience in drug-linker chemistry and ADC. In his decades of experience with AbbVie Inc., he has run the scale-up, regulatory strategy and development for conjugated therapeutics.
Now he is an independent consultant who suggests to biotech companies regarding the development and ADC CMC strategy. Now, Rob will be guiding the Defence’s CMC ideas as Accum®-improved ADC programs will be achieving milestones in clinical development.
Danny Chui is a successful R&D scientific leader with above 20 years of experience in ADC development, next-generation biologics and therapeutic antibody discovery. Danny’s intensified expertise in preclinical pharmacology, in vivo model development and antibody engineering will navigate the advancement of Accum® into critical oncology applications.
Lastly, Brendan Hussey holds a PhD degree in biotechnology with a background in venture capital and investment banking, which positions him as an operator-investor. Brendan’s unified financial and scientific learning will promise the alignment of Defence’s pipeline and platform with evolving market opportunities and partners' expectations. The development of this SAB will double the power of the Defence’s Scientific Foundation and help to discover the key potential of its Accum® platform throughout the radiotherapeutics and antibody-related therapeutics.
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
